12:00 AM
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

NDV-3: Phase I data

A double-blind, placebo-controlled Phase I trial in 160 healthy volunteers showed that single doses of intramuscular 300 µg NDV-3 with or without alum adjuvant and single doses of intradermal 30 µg NDV-3 without alum adjuvant were well tolerated. All 3 formulations...

Read the full 184 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >